Medicine
from24/7 Wall St.
1 week agoForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Single-asset, pre-revenue biotech binaries face concentrated risk after large rallies, while better risk-reward may come from companies with stronger pipelines, funding, and commercial traction.